Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT Long-Acting Injectable in Schizophrenia
NCT07061288Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events at 3 weeks, Number of participants with adverse events of special interest at 3 weeks and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07061288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061288.